<DOC>
	<DOCNO>NCT01102231</DOCNO>
	<brief_summary>Radiochemotherapy standard treatment unresectable stage III non-small cell lung cancer . The investigator goal study efficacy toxicity promise association new agent ( cetuximab pemetrexed ) concurrent radiotherapy .</brief_summary>
	<brief_title>Chemoradiotherapy Stage III Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>nonsquamous stage III nonsmall cell lung cancer measurable disease ( RECIST 1.1 ) ECOG performance status 01 normal organ marrow function prior chest radiation therapy history cancer NSCLC ( except nonmelanoma skin cancer carcinoma situ cervix ) within last five year . Prior therapy know specific inhibitor EGFR . history severe allergic reaction prior therapy monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>